Abolon was mandated by Afinum, the DACH-based private equity firm, on its acquisition of a majority stake in Swiss biotech company evitria, which provides custom antibodies for research purposes.<\/p>\n
evitria has been conducting more than 30,000 transfections and has been producing more than 5,000 different antibodies to date. The company\u2019s success is based on a unique, highly standardized and automatized production process that minimizes throughput times and guarantees high concentrations and quality levels, thereby perfectly addressing its customers\u2019 need for specific, tailor-made antibodies. Its business model has allowed evitria to build a reputation of a superior biotech specialist and trustworthy outsourcing partner.<\/p>\n
The transaction has been closed today. The enterprise value was not made publicly available.
\nAbolon was exclusively mandated by Afinum.<\/p>\n","protected":false},"template":"","class_list":["post-782","abolon-transactions","type-abolon-transactions","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/abolongroup.com\/de\/wp-json\/wp\/v2\/abolon-transactions\/782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/abolongroup.com\/de\/wp-json\/wp\/v2\/abolon-transactions"}],"about":[{"href":"https:\/\/abolongroup.com\/de\/wp-json\/wp\/v2\/types\/abolon-transactions"}],"wp:attachment":[{"href":"https:\/\/abolongroup.com\/de\/wp-json\/wp\/v2\/media?parent=782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}